Catalio Capital Management, LP
13F Reported Value
ⓘ$532.1M
Holdings
39
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Catalio Capital Management, LP disclosed 39 positions worth $532.1M in its Form 13F-HR for Q2 2026, led by $AVLN (Avalyn Pharma Inc.) at 10.4% of the equity portfolio, followed by $JNJ and $GILD. During the quarter the fund opened 10 new positions and exited 12 — including a new stake in $AVLN and a full exit from $TERN. The portfolio is most concentrated in Healthcare (99.9% of disclosed assets). All figures are sourced directly from Catalio Capital Management, LP’s Form 13F-HR filing with the SEC under CIK 1958125.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$55.2M1,675,830 sh - 69.0#285
Quality
$35.3M138,946 sh - 57.4#1,095
Quality
$34.0M269,309 sh - 36.9
Quality
$33.9M455,041 sh - 33.8
Quality
$26.6M1,215,698 sh - —
Quality
$26.5M562,672 sh - 70.4
Quality
$23.8M412,961 sh - —
Quality
$22.6M824,043 sh - 53.5
Quality
$22.3M82,181 sh - 77.4
Quality
$21.7M191,627 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Avalyn Pharma Inc.$AVLN | — | $55.2M | 1,675,830 |
 JOHNSON & JOHNSON$JNJ | 69.0#285 | $35.3M | 138,946 |
 GILEAD SCIENCES, INC.$GILD | 57.4#1,095 | $34.0M | 269,309 |
 BridgeBio Pharma, Inc.$BBIO | 36.9 | $33.9M | 455,041 |
 Syndax Pharmaceuticals Inc$SNDX | 33.8 | $26.6M | 1,215,698 |
 Definium Therapeutics, Inc.$DFTX | — | $26.5M | 562,672 |
 BRISTOL MYERS SQUIBB CO$BMY | 70.4 | $23.8M | 412,961 |
 Parabilis Medicines, Inc.$PBLS | — | $22.6M | 824,043 |
 Natera, Inc.$NTRA | 53.5 | $22.3M | 82,181 |
 INCYTE CORP$INCY | 77.4 | $21.7M | 191,627 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Catalio Capital Management, LP's 39 positions.
Showing top 10 of 39 holdings.
Sector Allocation
Healthcare
$531.7M
Other
$367,950
Full Holdings — Catalio Capital Management, LP (Q2 2026)
All 39 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AVLN | Avalyn Pharma Inc. | $55.2M | 10.4% | NEW | — |
| 2 | $JNJ | JOHNSON & JOHNSON | $35.3M | 6.6% | NEW | 69 |
| 3 | $GILD | GILEAD SCIENCES, INC. | $34.0M | 6.4% | +64% | 57.4 |
| 4 | $BBIO | BridgeBio Pharma, Inc. | $33.9M | 6.4% | +5% | 36.9 |
| 5 | $SNDX | Syndax Pharmaceuticals Inc | $26.6M | 5.0% | +16% | 33.8 |
| 6 | $DFTX | Definium Therapeutics, Inc. | $26.5M | 5.0% | -46% | — |
| 7 | $BMY | BRISTOL MYERS SQUIBB CO | $23.8M | 4.5% | -2% | 70.4 |
| 8 | $PBLS | Parabilis Medicines, Inc. | $22.6M | 4.2% | NEW | — |
| 9 | $NTRA | Natera, Inc. | $22.3M | 4.2% | +16% | 53.5 |
| 10 | $INCY | INCYTE CORP | $21.7M | 4.1% | +5% | 77.4 |
| 11 |  $SEPN | Septerna, Inc. | $18.0M | 3.4% | +82% | 59.2 |
| 12 |  $MLYS | Mineralys Therapeutics, Inc. | $17.5M | 3.3% | +48% | — |
| 13 |  $HTFL | Heartflow, Inc. | $17.1M | 3.2% | +44% | 34.3 |
| 14 |  $CRVS | Corvus Pharmaceuticals, Inc. | $16.1M | 3.0% | +21% | — |
| 15 |  $GPCR | Structure Therapeutics Inc. | $14.8M | 2.8% | +8% | — |
| 16 |  $PTGX | Protagonist Therapeutics, Inc | $13.1M | 2.5% | NEW | 59.4 |
| 17 |  $IRON | Disc Medicine, Inc. | $11.7M | 2.2% | +30% | — |
| 18 |  $EW | Edwards Lifesciences Corp | $11.3M | 2.1% | -14% | 69.4 |
| 19 |  $AXSM | Axsome Therapeutics, Inc. | $10.6M | 2.0% | NEW | 40.8 |
| 20 |  $RARE | Ultragenyx Pharmaceutical Inc. | $10.6M | 2.0% | -63% | 34.2 |
| 21 |  $KLRA | Kailera Therapeutics, Inc. | $10.3M | 1.9% | NEW | — |
| 22 |  $KPTI | Karyopharm Therapeutics Inc. | $9.2M | 1.7% | +5% | 15.1 |
| 23 |  $ODTX | Odyssey Therapeutics, Inc. | $8.6M | 1.6% | NEW | — |
| 24 |  $ASND | Ascendis Pharma A/S | $8.5M | 1.6% | -75% | 44.8 |
| 25 |  $KARD | Kardigan, Inc. | $7.5M | 1.4% | NEW | — |
| 26 |  $ELDN | Eledon Pharmaceuticals, Inc. | $6.7M | 1.3% | +3% | — |
| 27 |  $FDMT | 4D Molecular Therapeutics, Inc. | $6.3M | 1.2% | NEW | 34.5 |
| 28 |  $MANE | Veradermics, Inc | $5.6M | 1.1% | -74% | — |
| 29 |  $DYN | Dyne Therapeutics, Inc. | $5.4M | 1.0% | -13% | — |
| 30 |  $GUTS | FRACTYL HEALTH, INC. | $4.9M | 0.9% | +12% | 10 |
| 31 |  $IMCR | Immunocore Holdings plc | $4.7M | 0.9% | +76% | — |
| 32 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $3.2M | 0.6% | -94% | 22.6 |
| 33 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $2.4M | 0.5% | NEW | — |
| 34 |  $TARA | Protara Therapeutics, Inc. | $2.0M | 0.4% | -10% | — |
| 35 |  $HYPR | Hyperfine, Inc. | $1.8M | 0.3% | +0% | — |
| 36 |  $ATAI.R1840904 | Atai Beckley N.V. | $1.0M | 0.2% | +0% | — |
| 37 |  $MGX | Metagenomi Therapeutics, Inc. | $629,502 | 0.1% | +0% | 5.7 |
| 38 |  $OM | Outset Medical, Inc. | $510,965 | 0.1% | +0% | 18.5 |
| 39 | — | FAETH THERAPEUTICS INC - COM NEW | $367,950 | 0.1% | +0% | — |
New Positions (10)
$AVLN Avalyn Pharma Inc.$55.2M$JNJ JOHNSON & JOHNSON$35.3M$PBLS Parabilis Medicines, Inc.$22.6M$PTGX Protagonist Therapeutics, Inc$13.1M$AXSM Axsome Therapeutics, Inc.$10.6M$KLRA Kailera Therapeutics, Inc.$10.3M$ODTX Odyssey Therapeutics, Inc.$8.6M$KARD Kardigan, Inc.$7.5M$FDMT 4D Molecular Therapeutics, Inc.$6.3M$BBOT BridgeBio Oncology Therapeutics, Inc.$2.4MExited Positions (12)
$TERN Terns Pharmaceuticals, Inc.
$SLNO SOLENO THERAPEUTICS INC
$BSX BOSTON SCIENTIFIC CORP
$CYTK CYTOKINETICS INC
$ADPT Adaptive Biotechnologies Corp
$KALV KalVista Pharmaceuticals, Inc.
$QURE uniQure N.V.
$ABVX Abivax S.A.
$SUPN SUPERNUS PHARMACEUTICALS, INC.
$PHAT Phathom Pharmaceuticals, Inc.
$NAMS NewAmsterdam Pharma Co N.V.
$TYRA Tyra Biosciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Catalio Capital Management, LP including:
Track Catalio Capital Management, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Catalio Capital Management, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Catalio Capital Management, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Catalio Capital Management, LP (SEC CIK: 1958125), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Catalio Capital Management, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.